ReNeuron Group has expanded its intellectual property estate through the grant of several key patents covering its exosome technology platform. These new patents have been recently issued covering ReNeuron’s neural stem cell-derived exosomes and their methods of production. Following these patent grants, ReNeuron’s patent estate consists of over 40 patents globally, covering its cell-based therapies and exosome technology.
Patents granted in China, Korea, Japan and Europe include claims to a method of producing exosomes derived from differentiated stem cells, methods of production and composition of matter for exosomes derived from the company’s CTX neural stem cells. One more patent has been issued in Japan with for the use of a neural stem cell exosome in the treatment of glioma (brain cancer).
ReNeuron’s exosome platform has been the subject of a collaboration with an un-named US biotechnology company in the last year and ReNeuron intends to license this drug delivery technology further for the delivery of innovative gene therapy and gene silencing therapies.
Olav Hellebø, ReNeuron’s CEO, commented: “We expect to build this patent estate further in the near future. The recent and expected grants will stand us in good stead as we seek valuable collaboration deals to exploit ReNeuron’s exosome platform as a novel system for delivering advanced therapeutics such as gene therapies.